Dose-Dependent Radiation and Chemotherapy Risks for Colorectal Subsequent Malignancies in Childhood Cancer Survivors: Clinical Implications from a CCSS Analysis
Posted innews Oncology Pediatrics

Dose-Dependent Radiation and Chemotherapy Risks for Colorectal Subsequent Malignancies in Childhood Cancer Survivors: Clinical Implications from a CCSS Analysis

A CCSS analysis of 25,723 five-year childhood cancer survivors shows clear dose-response relationships between colorectum-specific radiation dose, irradiated colorectal volume, several chemotherapy exposures (notably procarbazine, high alkylator and platinum doses), and subsequent colorectal cancers, with actionable implications for RT planning and survivorship surveillance.
Mosunetuzumab + Polatuzumab Vedotin Outperforms R‑GemOx in Transplant‑Ineligible Relapsed/Refractory Large B‑Cell Lymphoma: Primary Results of the Phase III SUNMO Trial
Posted inHematology-Oncology news Oncology

Mosunetuzumab + Polatuzumab Vedotin Outperforms R‑GemOx in Transplant‑Ineligible Relapsed/Refractory Large B‑Cell Lymphoma: Primary Results of the Phase III SUNMO Trial

In the randomized phase III SUNMO trial, mosunetuzumab plus polatuzumab vedotin significantly improved response rates and progression‑free survival versus R‑GemOx in transplant‑ineligible relapsed/refractory large B‑cell lymphoma, with low rates of clinically significant cytokine release syndrome and improved patient‑reported outcomes.
Hepatic Arterial Infusion of Floxuridine Plus Systemic Gemcitabine–Cisplatin Substantially Improves Survival for Liver‑Confined Unresectable Intrahepatic Cholangiocarcinoma: PUMP‑2 Trial Results
Posted innews Oncology

Hepatic Arterial Infusion of Floxuridine Plus Systemic Gemcitabine–Cisplatin Substantially Improves Survival for Liver‑Confined Unresectable Intrahepatic Cholangiocarcinoma: PUMP‑2 Trial Results

The PUMP‑2 phase II trial reports that hepatic arterial infusion (HAIP) of floxuridine combined with systemic gemcitabine–cisplatin achieved a 1‑year overall survival of 80% and median OS of 22.3 months in unresectable liver‑confined intrahepatic cholangiocarcinoma, surpassing historical gem‑cis cohorts.
Ifinatamab Deruxtecan Shows Promising Activity in Previously Treated Extensive‑Stage SCLC: Primary Analysis of Phase II IDeate‑Lung01
Posted innews Oncology

Ifinatamab Deruxtecan Shows Promising Activity in Previously Treated Extensive‑Stage SCLC: Primary Analysis of Phase II IDeate‑Lung01

In the phase II IDeate‑Lung01 trial, ifinatamab deruxtecan (I‑DXd) at 12 mg/kg every 3 weeks produced a confirmed ORR of 48.2% and median PFS 4.9 months in heavily pretreated extensive‑stage small cell lung cancer (ES‑SCLC), with an adjudicated treatment‑related ILD rate of 12.4%. Results support further development with careful ILD monitoring.
Five-Year ZUMA-5 Follow-Up: Durable Remissions and Potential for Cure with Axicabtagene Ciloleucel in Relapsed/Refractory Follicular Lymphoma
Posted inHematology-Oncology news Oncology

Five-Year ZUMA-5 Follow-Up: Durable Remissions and Potential for Cure with Axicabtagene Ciloleucel in Relapsed/Refractory Follicular Lymphoma

Five-year outcomes from ZUMA-5 show axi-cel produces high response rates in relapsed/refractory indolent NHL, with 75% CR, median PFS ~62 months, durable remissions linked to early CAR T expansion and naïve T-cell product phenotype, and an acceptable long-term safety profile.
Carboplatin in Neoadjuvant Chemotherapy for Triple‑Negative Breast Cancer: No EFS Gain but an Overall Survival Signal Driven by Premenopausal Patients
Posted innews Oncology

Carboplatin in Neoadjuvant Chemotherapy for Triple‑Negative Breast Cancer: No EFS Gain but an Overall Survival Signal Driven by Premenopausal Patients

A phase III trial found that adding weekly carboplatin to taxane‑anthracycline neoadjuvant chemotherapy did not significantly improve event‑free survival overall but was associated with improved overall survival, with benefits concentrated in premenopausal women; hematologic toxicity increased.
Long-Term Nirogacestat for Progressive Desmoid Tumors: Durable Responses, Continued Tumor Shrinkage, and a Manageable Safety Profile
Posted inHematology-Oncology news Oncology

Long-Term Nirogacestat for Progressive Desmoid Tumors: Durable Responses, Continued Tumor Shrinkage, and a Manageable Safety Profile

Extended follow-up from the phase III DeFi trial shows that continuous nirogacestat yields further tumor shrinkage, durable objective responses (ORR 45.7% at up to 4 years), sustained patient-reported benefits, and a consistent, manageable safety profile over a median 33.6 months of exposure.
PASS-01: Gemcitabine/Nab‑Paclitaxel Shows an Overall Survival Edge Over Modified FOLFIRINOX in First‑Line Metastatic PDAC — Biomarker Correlatives Underscore Need to Move Precision Upstream
Posted innews Oncology

PASS-01: Gemcitabine/Nab‑Paclitaxel Shows an Overall Survival Edge Over Modified FOLFIRINOX in First‑Line Metastatic PDAC — Biomarker Correlatives Underscore Need to Move Precision Upstream

In the randomized phase II PASS‑01 trial of first‑line metastatic pancreatic ductal adenocarcinoma (PDAC), progression‑free survival was similar between modified FOLFIRINOX and gemcitabine/nab‑paclitaxel, but overall survival and safety trends favored gemcitabine/nab‑paclitaxel. Molecular profiling and organoid work were feasible but second‑line, correlate‑guided therapy showed limited benefit.